With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.
(1)L-glutamic acid dibenzyl ester hydrochloride (86.9 mg),Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate(114 mg), DMF (2 mL) and DIEA (100 muL)HBTU (83 mg) was added, and the mixture was stirred at room temperature for 30 minutes. The solvent was distilled off under reduced pressure,Ethyl acetate (5 mL) and saturated aqueous sodium chloride solution (3 mL) were added to the residue.The organic layer was separated and the aqueous layer was extracted 5 times with ethyl acetate (5 mL).The combined organic layer was dried over anhydrous magnesium sulfate,Purification by silica gel column chromatography (ethyl acetate)(H1) (96 mg)., 137076-54-1
The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI